FIELD: medicine.
SUBSTANCE: invention refers to medicine and pharmacology, and represents the use of at least one cytokine of IL-6 family for making a pharmaceutical composition for joint administration with at least one IFN -α for treating viral diseases, herewith said cytokine is chosen from oncostatin M, cardiotrophine-1 and their combinations.
EFFECT: invention provides overcoming an inhibiting effect of VHC on STAT3 phosphorilation which occurs when cells are incubated with INF-α or with cytokine of IL-6 family (eg CT-1 or OSM) only, higher induction of interferon sensitive genes (ISG), eg 2'-5'-oligoadenylate synthase (2'-5'OAS), and increased levels STAT1 and STAT3, in comparison with cells which are incubated with cytokine only, and more effective virus replication inhibition, than when using cytokine only, as well as manifestation of a strong synergetic relation of IFN-α and CT-1, or IFN -α and OSM.
38 cl, 5 ex, 3 tbl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF FORMATION OF VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C | 2011 |
|
RU2461834C1 |
| OPTIMIZED RECOMBINANT PROTEIN ENCODING GENE - HUMAN INTERFERON ALPHA-17 ANALOG | 2015 |
|
RU2620073C2 |
| APPLICATION OF MYXOMA VIRUS FOR THERAPEUTIC TREATMENT OF CANCER AND CHRONIC VIRUS INFECTION | 2004 |
|
RU2362584C2 |
| PEGYLATED INTERFERON LAMBDA WITH HIGH BIOACCESSABILITY IN ORAL USE AND METHOD FOR PRODUCTION THEREOF | 2017 |
|
RU2678332C1 |
| METHODS FOR IMPROVING PHARMACOKINETICS | 2010 |
|
RU2591830C2 |
| DOSAGE FORMS | 2005 |
|
RU2393863C2 |
| NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON | 2010 |
|
RU2447083C1 |
| PANGENOTYPIC NS5A PROTEIN INHIBITOR OF HEPATITIS C VIRUS, A PHARMACEUTICAL COMPOSITION AND METHODS FOR PREPARING AND USING | 2019 |
|
RU2723482C1 |
| USE OF COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT | 2006 |
|
RU2461630C2 |
| PEG-MODIFIED HUMAN INTERFERON β-1a MOLECULE WITH ANTIVIRAL, IMMUNOMODULATORY AND ANTIPROLIFERATIVE ACTIVITY, WITH IMPROVED STABILITY, REDUCED IMMUNOGENICITY, IMPROVED PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS, SUITABLE FOR MEDICAL USE, AND IMMUNOBIOLOGICAL FORMULATION BASED THEREON | 2013 |
|
RU2576372C2 |
